hotspot -WSS

hotspot

author：knowledge 2025-10-01 21:33:18 - browse：513

Adam's take main illustration — Molly Ferguson/STAT

This week, a preview of the TUDCA study in ALS and thoughts on how it might impact Amylyx Pharmaceuticals. Also, I chatted with CRISPR Therapeutics CEO Sam Kulkarni about its new investor. Read to the end for some burning questions, random thoughts.

The next ALS data readout — overdue but important

A European academic consortium is expected to announce results soon from a clinical trial investigating the use of a widely available nutritional supplement called tauroursodeoxycholic acid, or TUDCA, in people living with ALS. The outcome of the TUDCA-ALS study could have implications for Amylyx Pharmaceuticals, because TUDCA is one of the two main ingredients in Relyvrio, the company’s approved drug for ALS.

In a recent interview at Amylyx’s Kendall Square headquarters, co-CEOs Justin Klee and Josh Cohen mostly downplayed the suggestion that results from the randomized, placebo-controlled TUDCA study might affect Relyvrio negatively, or even positively.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Doctors' information doesn't help them choose wisely when sick

WSS

Robert F. Kennedy is pitching centrism on health, even on abortion

FDA approves first blood sugar monitor without finger pricks

Hundreds of thousands march in Israel. Former security chiefs beg Netanyahu to halt legal overhaul

My chronic pain journey would have been easier knowing 5 things % STAT

Medicare Advantage proposed rates disappoint insurers

Biogen Alzheimer’s drug launch off to slow start

hotspot

hotspot

The next ALS data readout — overdue but important

knowledge

As demand for Covid shots wanes, Moderna seeks its next success

What we’ve learned from the Aduhelm mess

The cancer drug shortage isn’t new — and neither are the solutions

What should King Charles tell the public about his cancer?

Bright Health sells Medicare Advantage business to Molina

Biogen Alzheimer’s drug launch off to slow start

State Dept. review finds Biden bears some blame for Afghanistan failures

What Henrietta Lacks's story taught me about my role as a doctor

Alkermes shareholders re

Robert F. Kennedy is pitching centrism on health, even on abortion

hotspot

Men with early prostate cancer can safely opt out of treatment

Inside the culture of fear in the White House science office of Eric Lander

Charges dismissed against white woman who spat on Black woman during protests in Connecticut

Why did Pfizer dish out millions for a Super Bowl ad?

Drone hits Crimean ammunition depot as strikes kill, wound civilians and journalists in Ukraine

For Medicare Advantage, Democrats want stronger protections around AI

hotspot

knowledge

focus

Wikipedia